Skip to main content
. 2018 Jul 9;2(13):1608–1615. doi: 10.1182/bloodadvances.2018017186

Figure 2.

Figure 2.

Survival for patients treated with lenalidomide vs no maintenance therapy. Patients receiving post-ASCT lenalidomide maintenance therapy had improved (A) PFS (P < .001) and (B) OS (P = .005) compared with those who did not receive maintenance therapy. Analysis was adjusted for covariates of ECOG performance status, serum creatinine level, treatment with a novel agent, treatment with lenalidomide, treatment with bortezomib, and triplet treatment during first-line induction therapy.